NICE won't endorse NHS coverage of Bristol's RA drug Orencia

03/29/2011 | Wall Street Journal, The

The U.K. National Institute for Health and Clinical Excellence said Bristol-Myers Squibb's Orencia, or abatacept, is not cost-effective for National Health Service use as second-line treatment for adults with moderate to severe rheumatoid arthritis who did not respond to standard nonbiologic medicines. The agency said it already endorsed coverage of several other RA drugs.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ